Biomarkers in cancer最新文献_第7页

Trisomy 8 Acute Myeloid Leukemia Analysis Reveals New Insights of DNA Methylome with Identification of HHEX as Potential Diagnostic Marker. Trisomy 8急性髓细胞白血病分析揭示了DNA甲基化的新见解，HHEX被鉴定为潜在的诊断标记。

Biomarkers in cancer Pub Date : 2015-01-29 eCollection Date: 2015-01-01 DOI: 10.4137/BIC.S19614

Marwa H Saied, Jacek Marzec, Sabah Khalid, Paul Smith, Gael Molloy, Bryan D Young

{"title":"Trisomy 8 Acute Myeloid Leukemia Analysis Reveals New Insights of DNA Methylome with Identification of HHEX as Potential Diagnostic Marker.","authors":"Marwa H Saied, Jacek Marzec, Sabah Khalid, Paul Smith, Gael Molloy, Bryan D Young","doi":"10.4137/BIC.S19614","DOIUrl":"10.4137/BIC.S19614","url":null,"abstract":"<p><p>Trisomy 8 acute myeloid leukemia (AML) is the commonest numerical aberration in AML. Here we present a global analysis of trisomy 8 AML using methylated DNA immunoprecipitation-sequencing (MeDIP-seq). The study is based on three diagnostic trisomy 8 AML and their parallel relapse status in addition to nine non-trisomic AML and four normal bone marrows (NBMs). In contrast to non-trisomic DNA samples, trisomy 8 AML showed a characteristic DNA methylation distribution pattern because an increase in the frequency of the hypermethylation signals in chromosome 8 was associated with an increase in the hypomethylation signals in the rest of the chromosomes. Chromosome 8 hypermethylation signals were found mainly in the CpG island (CGI) shores and interspersed repeats. Validating the most significant differentially methylated CGI (P = 7.88 × 10(-11)) identified in trisomy 8 AML demonstrated a specific core region within the gene body of HHEX, which was significantly correlated with HHEX expression in both diagnostic and relapse trisomy 8 AMLs. Overall, the existence of extra chromosome 8 was associated with a global impact on the DNA methylation distribution with identification of HHEX gene methylation as a potential diagnostic marker for trisomy 8 AML. </p>","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 ","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2015-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S19614","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33047852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

SIGNALING PATHWAYS AS BIOMARKERS 信号通路作为生物标志物

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S37778

A. Sahasrabuddhe, D. Rolland, P. Banerjee

引用次数: 0

Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy 难治性肾上腺皮质癌的分子分析和治疗的预测性生物标志物

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S34292

S. Millis, S. Ejadi, M. Demeure

{"title":"Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy","authors":"S. Millis, S. Ejadi, M. Demeure","doi":"10.4137/BIC.S34292","DOIUrl":"https://doi.org/10.4137/BIC.S34292","url":null,"abstract":"Purpose Current first-line chemotherapy for patients with metastatic adrenocortical cancer (ACC) includes doxorubicin, etoposide, cisplatin, and mitotane with a reported response rate of only 23.2%. New therapeutic leads for patients with refractory tumors are needed; there is no standard second-line treatment. Methods Samples from 135 ACC tumors were analyzed by immunohistochemistry, in situ hybridization (FISH or CISH), and/or gene sequencing at a single commercial reference laboratory (Caris Life Sciences) to identify markers associated with drug sensitivity and resistance. Results Overexpression of proteins related to demonstrated chemotherapy sensitivity or resistance included topoisomerase 1, progesterone receptor, and topoisomerase 2-alpha in 46%, 63%, and 42% of cases, respectively. Loss of excision repair cross-complementary group 1 (ERCC1), phosophatase and tensin homolog, O(6)-methylguanine-methyltransferase, and ribonucleotide reductase M1 (RRM1) was identified in 56%, 59%, 71%, and 58% of cases, respectively. Other aberrations included overexpression of programmed death-ligand 1 or programmed cell death protein 1 tumor-infiltrating lymphocytes in >40% of cases. In all, 35% of cases had a mutation in the canonical Wnt signaling pathway (either CTNNB1 or APC) and 48% had a mutation in TP53. No other genomic alterations were identified. Conclusion Biomarker alterations in ACC may be used to direct therapies, including recommendations for and potential resistance of some patients to traditional chemotherapies, which may explain the low response rate in the unselected population. Limited outcomes data support the use of mitotane and platinum therapies for patients with low levels of the proteins RRM1 and ERCC1.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"69 - 76"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S34292","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70687105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma let-7a-5p和let-7f-5p微rna在早期结直肠癌血浆和粪便样本中的同时低表达

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S25252

Reza Ghanbari, N. Mosakhani, V. Sarhadi, G. Armengol, N. Nouraee, A. Mohammadkhani, S. Khorrami, E. Arefian, M. Paryan, R. Malekzadeh, S. Knuutila

{"title":"Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma","authors":"Reza Ghanbari, N. Mosakhani, V. Sarhadi, G. Armengol, N. Nouraee, A. Mohammadkhani, S. Khorrami, E. Arefian, M. Paryan, R. Malekzadeh, S. Knuutila","doi":"10.4137/BIC.S25252","DOIUrl":"https://doi.org/10.4137/BIC.S25252","url":null,"abstract":"Colorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer death worldwide. Early detection of CRC can improve patient survival rates; thus, the identification of noninvasive diagnostic markers is urgently needed. MicroRNAs (miRNAs) have extensive potential to diagnose several diseases, including cancer. In this study, we compared the expression pattern of miRNAs from plasma and stool samples of patients with early stages of CRC (I, II) with that of healthy subjects. We performed miRNA profiling using microarrays on plasma and stool samples of eight patients with CRC and four healthy subjects. Seven miRNAs were found to be underexpressed in both plasma and stool samples of patients with CRC versus healthy subjects. Then, we aimed to verify two out of these seven differentially expressed miRNAs (let-7a-5p and let-7f-5p) by quantitative reverse transcriptase polymerase chain reaction on a larger set of plasma and stool samples of 51 patients with CRC and 26 healthy subjects. We confirmed the results of microarray analysis since their expression was significantly lower in stool and plasma samples of patients with CRC. Moreover, receiver operating characteristic curve analysis demonstrated that fecal let-7f expression levels have significant sensitivity and specificity to distinguish between patients with CRC and healthy subjects. In conclusion, if the results are confirmed in larger series of patients, underexpressed let-7a-5p and let-7f-5p miRNAs in both plasma and stool samples of patients with CRC may serve potentially as noninvasive molecular biomarkers for the early detection of CRC.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"39 - 48"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S25252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70686228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

Associations of the A66G Methionine Synthase Reductase Polymorphism in Colorectal Cancer: A Systematic Review and Meta-Analysis A66G蛋氨酸合成酶还原酶多态性与结直肠癌的关系:系统综述和荟萃分析

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S25251

N. Pabalan, E. Singian, Lani Tabangay, H. Jarjanazi, Neetu Singh

{"title":"Associations of the A66G Methionine Synthase Reductase Polymorphism in Colorectal Cancer: A Systematic Review and Meta-Analysis","authors":"N. Pabalan, E. Singian, Lani Tabangay, H. Jarjanazi, Neetu Singh","doi":"10.4137/BIC.S25251","DOIUrl":"https://doi.org/10.4137/BIC.S25251","url":null,"abstract":"Inconsistency in the reported associations between the A66G polymorphism in the methionine synthase reductase (MTRR) gene and colorectal cancer (CRC) prompted a meta-analysis, so that we could obtain a more precise estimate. Databases searches of the published literature yielded 20 case-control studies from 17 articles (8,371 cases and 12,574 controls). We calculated pooled odds ratios (ORs) and 95% confidence intervals in three genetic comparisons (A allele, G allele, and A/G genotype). We found no evidence of overall associations between MTRR A66G and CRC risk (OR 0.96–1.05, P = 0.12–0.44). This was materially unchanged when reanalyzed without the Hardy-Weinberg equilibrium (HWE)-deviating studies (OR 0.97–1.06, P = 0.11–0.65). In the A allele comparison, however, outlier treatment generated significant protection (OR 0.91, P = 0.01). Combined removal of the outliers and HWE-deviating studies reflected this summary effect (OR 0.90, P = 0.01) as did the pooled OR from high-quality studies (OR 0.90, P = 0.01). Only the Asian subgroup showed significant (both at P = 0.05) A allele (OR 1.13) and A/G genotype (OR 0.88) associations. In conclusion, post-outlier A allele effects were protective. Our study also suggests ethnic-specific associations with Asian susceptibility and protection in the A allele and A/G genotype comparisons, respectively. Folate status showed no association of this polymorphism with CRC.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"21 - 28"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S25251","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70686603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Biomarkers of Angiogenesis in Colorectal Cancer 结直肠癌血管生成的生物标志物

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S25250

L. Mousa, M. Salem, S. Mikhail

引用次数: 74

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells 致癌基因过量:对致癌基因成瘾的癌细胞来说，过量是件坏事

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S29326

A. Amin, S. Rajan, M. Groysman, Praechompoo Pongtornpipat, J. Schatz

引用次数: 16

Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer 间质成纤维细胞和巨噬细胞在结肠癌中的预后和预测意义

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S25247

B. Owusu, M. Vaid, P. Kaler, L. Klampfer

{"title":"Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer","authors":"B. Owusu, M. Vaid, P. Kaler, L. Klampfer","doi":"10.4137/BIC.S25247","DOIUrl":"https://doi.org/10.4137/BIC.S25247","url":null,"abstract":"Colon cancer development and malignant progression are driven by genetic and epigenetic alterations in tumor cells and by factors from the tumor microenvironment. Cancer cells become reliant on the activity of specific oncogenes and on prosurvival and proliferative signals they receive from the abnormal environment they create and reside in. Accordingly, the response to anticancer therapy is determined by genetic and epigenetic changes that are intrinsic to tumor cells and by the factors present in the tumor microenvironment. Recent advances in the understanding of the involvement of the tumor microenvironment in tumor progression and therapeutic response are optimizing the application of prognostic and predictive factors in colon cancer. Moreover, new targets in the tumor microenvironment that are amenable to therapeutic intervention have been identified. Because stromal cells are with rare exceptions genetically stable, the tumor microenvironment has emerged as a preferred target for therapeutic drugs. In this review, we discuss the role of stromal fibroblasts and macrophages in colon cancer progression and in the response of colon cancer patients to therapy.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"29 - 37"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S25247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70686145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies 基于血液的生物标志物在大肠内窥镜检查和预测未来的恶性肿瘤

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S31330

T. Kring, T. B. Piper, L. Jørgensen, J. Olsen, H. Rahr, K. Nielsen, S. Laurberg, G. Davis, B. Dowell, J. Johansen, I. Christensen, N. Brünner, H. Nielsen

{"title":"Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies","authors":"T. Kring, T. B. Piper, L. Jørgensen, J. Olsen, H. Rahr, K. Nielsen, S. Laurberg, G. Davis, B. Dowell, J. Johansen, I. Christensen, N. Brünner, H. Nielsen","doi":"10.4137/BIC.S31330","DOIUrl":"https://doi.org/10.4137/BIC.S31330","url":null,"abstract":"Soluble cancer-related protein biomarker levels may be increased in subjects without findings at large bowel endoscopy performed due to symptoms associated with colorectal cancer. The present study focused on a possible association between increased biomarker levels in such subjects and subsequent development of malignant diseases. In a major study of 4,990 subjects undergoing large bowel endoscopy, 691 were without pathology and comorbidity. Plasma levels of TIMP-1, CEA, CA19-9, and YKL-40 were determined in samples collected just before endoscopy and compared with subsequent development of a malignant disease within a period of 7-8 years. The upper 90% limits of the reference levels of every single protein were used to differentiate between normal and increased levels. The levels were separated into three groups: 0, none of the biomarkers increased; 1, one biomarker increased; 2, two or more biomarkers increased. A total of 43 subjects developed a primary malignant disease in the observation period. Univariatly, increase of all four biomarkers was significantly associated with subsequent development of a malignant disease. A multivariate analysis showed that increased biomarker levels were associated with subsequent development of a malignant disease (P = 0.002). The cumulative risk of developing malignant disease within the first 5 years after endoscopy was group 0, 3.3%; group 1, 5.8%; group 2, 7.8%. It is concluded that increased levels of plasma TIMP-1, CEA, CA19-9, and serum YKL-40 at large bowel endoscopy without findings may be associated with an increased risk of developing a subsequent malignant disease.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"57 - 61"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S31330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70686314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar 卡塔尔研究甲磺酸伊马替尼治疗慢性髓系白血病患者α -酸性糖蛋白和蛋白糖蛋白存在的影响

Biomarkers in cancer Pub Date : 2015-01-01 DOI: 10.4137/BIC.S31427

Nader I. Al-Dewik, A. Jewell, M. Yassin, Hisham Morsi

{"title":"Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar","authors":"Nader I. Al-Dewik, A. Jewell, M. Yassin, Hisham Morsi","doi":"10.4137/BIC.S31427","DOIUrl":"https://doi.org/10.4137/BIC.S31427","url":null,"abstract":"Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha-1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) may reduce the intracellular concentration of the drug via an active pump mechanism. We thus investigated the correlation between AGP and PGP levels and the resistance/response to treatment. A total of 26 CML patients were investigated for AGP and PGP levels at diagnosis and during treatment. There was no significant difference or correlation between AGP levels and the different groups of patients. There was also no significant difference in the fluorescence intensities of PGP levels among the different patient groups. The resistance observed in our CML patient population could not be correlated with AGP and PGP levels. There was no significant pattern of AGP and PGP expression, irrespective of the response or resistance to treatment.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"7 1","pages":"63 - 67"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S31427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70686393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7